This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Kogenate FS

Bayer AG

Drug Names(s): Helixate NexGen, Kogenate SF, Kogenate Bayer, Antihemophilic Factor Recombinant, Formulated with Sucrose, BAY14-2222

Description: Kogenate is manufactured using recombinant DNA technology in a way that includes a purification and formulation process that eliminates the addition of albumin and incorporates sucrose as a stabilizer in the final formulation. Kogenate provides a means of temporarily replacing the missing clotting factor FVIII in order to correct or prevent bleeding episodes, allowing the body’s blood-clotting process to function properly. (Kogenate FS succeeded Kogenate (R), which was was approved in 1993 and contained human albumin as a stabilizer.)

Kogenate FS News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug